AQVESME® (mitapivat), FDA-Approved for Adults with Thalassemia, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for AQVESME, indicated for adults with non-transfusion-dependent or transfusion-dependent alpha- or beta-thalassemia.
KOMZIFTI® (ziftomenib), FDA-Approved for Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for Komzifti, an oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
INLURIYO™ (imlunestrant) FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for Inluriyo, an oral estrogen receptor antagonist for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer.
PALSONIFY™ (paltusotine), FDA-Approved for Treatment of Adults with Acromegaly Who Had an Inadequate Response to Surgery and/or for Whom Surgery Is Not an Option, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for PALSONIFY, the first once-daily oral therapy for adults with acromegaly who need an alternative to surgery.
Precigen Selects McKesson to Support Specialty Pharmacy and Patient Hub Services for Launch of Novel Immunotherapy
Biologics by McKesson, in partnership with InspiroGene by McKesson, was chosen as the exclusive specialty pharmacy for a newly approved immunotherapy for adults with recurrent respiratory papillomatosis.
InspiroGene by McKesson Selected as the Specialty Pharmacy Partner for Iovance’s Amtagvi®—First Cell Therapy Approved for Solid Tumors
Biologics by McKesson, in partnership with InspiroGene, supports Amtagvi, the first FDA-approved one-time cell therapy for a solid tumor in patients with unresectable or metastatic melanoma.
WAYRILZ™ (rilzabrutinib), FDA-Approved for Treatment of Adults with Immune Thrombocytopenia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for WAYRILZ, an oral BTK inhibitor for adults with persistent or chronic immune thrombocytopenia.
PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for VIJOICE, indicated for adults and children age 2 and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum.
ENSACOVE™ (ensartinib), FDA-Approved Treatment for Adult Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for ENSACOVE and exclusive hub services provider for adults with advanced ALK-positive non-small cell lung cancer.